Kampfschwein300 : News
NEUNKIRCHEN-RICHELBACH, GERMANY -- (Marketwired) -- 06/02/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced Cannabis Science Europe GmbH, a European subsidiary of Cannabis Science Inc., based in Germany, released the newest innovative product line: Canna POW! The first worldwide, premium quality, water soluble Cannabis Instant Beverage: Canna POW! Is starting distribution June 1, 2016, in Europe and Internationally.
Please visit http://www.dupetit.eu for International distributors and product buyers.
The Canna POW! unveiling took place June 1, 2016 at the EIHA Cannabis & CBD Conference in Germany and continues through to June 2, 2016. After many months of development with its partner Dupetit Natural Products GmbH, Cannabis Science Europe GmbH has managed to eliminate most of the THC as the basis of its worldwide first unique Cannabis Instant Beverage product line.
"The Canna POW! instant beverage is water-soluble and makes for an excellent grab-and-go drink option. The company has been developing this new line for months. After much research, the company was able to de-wax and eliminate most of the THC content in the beverage.
Generally, cannabinoids become unstable when mixed with water due to the oxidation process. By shipping the product in a powder form, the company was able to bypass this oxidation and provide a potent product that maintains full nutritional and CBD levels. The product line features the highest amounts of CBDA in the industry.
"The Canna POW! products, which are launching in Europe, come in five different flavors: Cafe & Chocolate, Grapefruit, Lime, Pomegranate, and Cocoa. The company is already working to develop other lines, including cosmetic lines and various extracts with different levels of THC and CBDA," stated Alfredo Dupetit, President & CEO, Cannabis Science Europe GmbH.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.